Bone and Mineral guidelines for patients with chronic kidney disease: A call for revision

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 179-183

  Andress, Dennis L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PRACTICE GUIDELINE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

HUMANS; HYPERPARATHYROIDISM, SECONDARY; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 38749138917     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01310307     Document Type: Short Survey

References (44)

1. Eknoyan G, Levin A, Levin NW: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lamiere N, Eknoyan G: Definition, evaluation and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
3. Braun J, Oldendorf M, Mosage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401, 1996
4. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IS: Coronary calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
5. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-992, 2001
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001
7. London GM, Guerin AP, Marchais SJ, Metevier F, Pannier B, Adda H: Arterial medial calcification in end-stage renal disease: Impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
8. Matsuoka M, Iseka K, Tamishoro M: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8: 54-58, 2004
9. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol 16: 507-513, 2005
10. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S: Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int 68: 1258-1266, 2005
11. Chertow GM, Burke SK, Raggi P: Treat to Goal Working Group: Sevelamer attenuates the risk of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
12. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM: Decrease in thoracic bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764-772, 2005
13. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
14. Gal-Moscovici A, Sprague SM: The role of calcimimetics in chronic kidney disease. Kidney Int 70: 568-572, 2006
15. Teng M, Wolf M, Ofstun MN, Lazarus JM, Hernan MA, Carmago CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
16. Teng M, Wolf M, Lowrie E, Ofthsun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol. N Engl J Med 349: 446-456, 2003
17. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
18. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrck RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
19. Young EW, Albert JM, Akiba T: Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns (DOPPS) [Abstract]. J Am Soc Nephrol 16: 278A, 2005
20. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, hiaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk of cardiovascular mortality in oral lalphahydroxyvitamin D3 users in a hemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004
21. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and mortality among hemodialysis patients Kidney Int 72: 1004-1013, 2007
22. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: 132-138, 2007
23. Zisman AL, Hristova M, Ho L, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36-43, 2007
24. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50: 59-68, 2007
25. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK: Calcitriol regress cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 102: 21-29, 2006
26. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104: 16810-16815, 2007
27. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin receptor activators on vascular calcification in uremic rats. Kidney Int 72: 709-715, 2007
28. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004
29. Block GA, Hulbert-Shearon TA, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
30. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
31. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 67: 217-226, 2005
32. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with pre-dialysis chronic renal failure. Kidney Int 56: 1084-1093, 1999
33. Rix M, Eskildsen P, Olgaard K: Effect of 18 months of treatment with alphacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19: 870-876, 2004
34. Hamdy NA, Kanis J, Beneton MN, Brown CB, Juttman JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alphacalcidol on the natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363, 1995
35. Haris A, Sherrard DJ, Hercz G: Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 70: 931-937, 2006
36. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
37. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26: 836-844, 1995
38. Qi Q, Monier-Faugere MC, Geng Z, Malluche H: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622-631, 1995
39. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella M, Mazzaferro S, Napoletano I, Sardella D, Taggi F: Bone markers in the diagnosis of low turnover bone osteodystrophy in hemodialysis patients. Nephrol Dial Transplant 13: 2294-2302, 1998
40. Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour P: Effects of oral calcitriol therapy on bone mineral density in patients with end-stage renal failure. Kidney Int 45: 245-252, 1994
41. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89: 4246-4253, 2004
42. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66: 2010-2016, 2004
43. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18:2401-2407, 2007
44. Uhlig K, MacLeod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lamiere N, Eknoyan G: Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70: 2058-2065, 2006